INT156672

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.74
First Reported 2008
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 12.15
Pain Relevance 1.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (SERPING1) extracellular region (SERPING1)
SERPING1 (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 51 99.84 Very High Very High Very High
Pain 16 97.12 Very High Very High Very High
abdominal pain 11 87.92 High High
Antihistamine 11 65.40 Quite High
Inflammation 4 18.56 Low Low
antagonist 14 5.00 Very Low Very Low Very Low
corticosteroid 5 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
b2 receptor 1 5.00 Very Low Very Low Very Low
Inflammatory mediators 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hereditary Angioedema 365 100.00 Very High Very High Very High
Pressure And Volume Under Development 322 100.00 Very High Very High Very High
Disease 57 99.92 Very High Very High Very High
Emergencies 24 97.84 Very High Very High Very High
Body Weight 6 92.80 High High
Abdominal Pain 11 87.92 High High
Urticaria 20 86.80 High High
Shock 2 86.64 High High
Pain 9 85.36 High High
Hypotension 1 85.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The disease is caused by an aberrant C1 esterase inhibitor (C1-INH), which regulates complement, fibrinolytic, and contact pathways.
Localization (aberrant) of C1 esterase inhibitor associated with disease
1) Confidence 0.74 Published 2008 Journal Recent patents on inflammation & allergy drug discovery Section Abstract Doc Link 19076006 Disease Relevance 1.10 Pain Relevance 0.23
The disease is caused by an aberrant C1 esterase inhibitor (C1-INH), which regulates complement, fibrinolytic, and contact pathways.
Localization (caused) of C1 esterase inhibitor associated with disease
2) Confidence 0.74 Published 2008 Journal Recent patents on inflammation & allergy drug discovery Section Abstract Doc Link 19076006 Disease Relevance 1.11 Pain Relevance 0.23
The disease is caused by an aberrant C1 esterase inhibitor (C1-INH), which regulates complement, fibrinolytic, and contact pathways.
Localization (aberrant) of C1-INH associated with disease
3) Confidence 0.73 Published 2008 Journal Recent patents on inflammation & allergy drug discovery Section Abstract Doc Link 19076006 Disease Relevance 1.11 Pain Relevance 0.23
The disease is caused by an aberrant C1 esterase inhibitor (C1-INH), which regulates complement, fibrinolytic, and contact pathways.
Localization (caused) of C1-INH associated with disease
4) Confidence 0.73 Published 2008 Journal Recent patents on inflammation & allergy drug discovery Section Abstract Doc Link 19076006 Disease Relevance 1.11 Pain Relevance 0.23
Appropriate use of treatment product(s) (pdC1INH, rhC1INH, icatibant)
Localization (use) of C1INH
5) Confidence 0.73 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2922091 Disease Relevance 0.35 Pain Relevance 0
Appropriate use of treatment product(s) (pdC1INH, rhC1INH, icatibant)
Localization (use) of C1INH
6) Confidence 0.73 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2922091 Disease Relevance 0.35 Pain Relevance 0
This recombinant C1-INH is then secreted into rabbit milk and is purified.
Localization (secreted) of recombinant C1-INH
7) Confidence 0.68 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.57 Pain Relevance 0
Cutaneous angioedema in HAE patients is typically localized to the extremities.
Localization (localized) of HAE associated with pressure and volume under development
8) Confidence 0.65 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 1.88 Pain Relevance 0.15
This testing includes determination of C1q which is reduced in 70% of patients with AAE and is normal in HAE.
Spec (determination) Localization (determination) of HAE associated with pressure and volume under development
9) Confidence 0.65 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 0.95 Pain Relevance 0
These processes result in a sequence of C1-inhibitor consumption, complement activation, and release of bradykinin during every acute attack until appropriate therapy is administered to raise serum levels of C1-inhibitor, or until remission spontaneously occurs [1,8].


Localization (release) of C1-inhibitor associated with bradykinin
10) Confidence 0.64 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 0.58 Pain Relevance 0.12
Therefore they can be clearly separated from HAE type III.


Localization (separated) of HAE type III associated with hereditary angioedema
11) Confidence 0.62 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2919521 Disease Relevance 3.04 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox